Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role?

The disease caused by the new coronavirus SARS-CoV-2 (COVID-19) is currently spread worldwide . Recent data supports SARS-CoV-2 may use integrins to enter human cells. Therefore, anti-integrins therapies might be an alternative against the infection . Natalizumab, approved for Multiple Sclerosis (MS...

Descripción completa

Detalles Bibliográficos
Autores principales: Aguirre, Clara, Meca-Lallana, Virginia, Barrios-Blandino, Ana, del Río, Beatriz, Vivancos, Jose
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831671/
https://www.ncbi.nlm.nih.gov/pubmed/32531754
http://dx.doi.org/10.1016/j.msard.2020.102250

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831671/
https://www.ncbi.nlm.nih.gov/pubmed/32531754
http://dx.doi.org/10.1016/j.msard.2020.102250

Ejemplares similares